Mathilde Argote,Guillaume Sescousse,Jérôme Brunelin,Grégoire Baudin,Michael Patrick Schaub,Rachel Rabin,Thomas Schnell,Petter Andreas Ringen,Ole Andreas Andreassen,Jean Margaret Addington,Paolo Brambilla,Giuseppe Delvecchio,Andreas Bechdolf,Thomas Wobrock,Thomas Schneider-Axmann,Daniela Herzig,Christine Mohr,Regina Vila-Badia,Judith Usall Rodie,Jasmina Mallet,Valerio Ricci,Giovanni Martinotti,Karolína Knížková,Mabel Rodriguez,Jacob Cookey,Philip Tibbo,Freda Scheffler,Laila Asmal,Clemente Garcia-Rizo,Silvia Amoretti,Christian Huber,Heather Thibeau,Emily Kline,Eric Fakra,Renaud Jardri,Mikail Nourredine,Benjamin Rolland

Abstract:Background: The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias. Methods: PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172. Findings: Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]). Interpretation: No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution. Funding: This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.

The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study

The contribution of cannabis use to the increased psychosis risk among minority ethnic groups in Europe

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study

The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study

Aberrant salience in cannabis-induced psychosis: a comparative study

Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort

Schizophrenia and the Environment: Within-Person Analyses May be Required to Yield Evidence of Unconfounded and Causal Association—The Example of Cannabis and Psychosis

Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors

Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals

Variation of subclinical psychosis as a function of population density across different European settings: Findings from the multi‐national EU‐GEI study

Polygenic and Polyenvironment Interplay in Schizophrenia-Spectrum Disorder and Affective Psychosis; the EUGEI First Episode Study

Cannabis Use and Psychosis: A Longitudinal Population-based Study

Joint-trajectories of clinical severity, social functioning and cannabis use in first-episode psychosis: A 5-year longitudinal study in 2 urban early intervention services

Use of illicit substances in a psychosis incidence cohort: a comparison among different ethnic groups in the Netherlands.

Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study

Age-dependent association of cannabis use with risk of psychotic disorder

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Linking Substance Use with Symptoms of Subclinical Psychosis in a Community Cohort over 30 Years.

Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis